ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio, Inc. entered an exclusive development and supply agreement with Japan BCG Laboratory giving it sole rights to develop, import, sell, and distribute the Tokyo-172 strain of BCG for bladder cancer in the United States and its territories after potential FDA approval. JBL will manufacture and supply the product, while ImmunityBio leads all U.S. preclinical, clinical, regulatory, and commercialization activities, with no payments due before approval and a commitment to purchase at least two batches per year afterward. The Tokyo strain’s Phase III SWOG S1602 data showed non-inferiority to TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer, and this agreement complements ImmunityBio’s existing recombinant BCG partnership to help address chronic U.S. BCG shortages.
ImmunityBio, Inc. reported strong Q1 2026 growth driven by ANKTIVA, but a large accounting loss. Net product revenue reached about $44.2 million for the quarter, up ~168% versus Q1 2025 and 15% over Q4 2025, reflecting continued uptake of ANKTIVA.
GAAP net loss attributable to common stockholders widened to $632.8 million, largely from non-cash changes in the fair value of warrant and derivative liabilities and a related-party convertible note tied to a higher stock price, plus a write-off of a convertible note receivable and higher R&D and SG&A expenses. Adjusted net loss, which excludes these items, was $86.2 million.
Cash, cash equivalents and marketable securities increased to $380.9 million as of March 31, 2026, supported by $223.9 million of net cash provided by financing activities in the quarter. ANKTIVA is now approved or authorized across five regulatory jurisdictions covering about 34 countries, with expanding commercial availability, and a pivotal BCG-naïve NMIBC trial is fully enrolled with a supplemental BLA submission planned in 2026.
ImmunityBio, Inc. is asking stockholders to elect nine directors and ratify Deloitte & Touche LLP as auditor at its June 9, 2026 virtual annual meeting. The proxy also highlights ANKTIVA’s first full commercial year, with 2025 net product revenue of about $113 million, a 700% increase, and 750% unit sales growth. ANKTIVA has reimbursement coverage for more than 240 million lives and a permanent J-code. The company reports new approvals in the UK, EU and an SFDA accelerated approval in metastatic non-small cell lung cancer, plus progress in BCG-naïve bladder cancer, glioblastoma and Phase 3 NSCLC trials. Executives received modest base salary increases and equity-based incentives tied to performance.
ImmunityBio, Inc. reported preliminary Q1 2026 net product revenue of approximately $44.2 million, driven by continued adoption of its bladder cancer therapy ANKTIVA. This represents about a 168% year-over-year increase versus Q1 2025 and a 15% sequential rise from $38.3 million in Q4 2025.
Full-year 2025 net product revenue was $113 million, up roughly 700% from 2024, underscoring rapid commercial ramp. The company ended Q1 2026 with about $380.9 million in cash, cash equivalents and marketable securities. ANKTIVA is approved or authorized in five regulatory jurisdictions covering roughly 34 countries, and key bladder cancer trials are fully enrolled with a supplemental BLA targeted in 2026.
ImmunityBio, Inc. filed a Form 8-K after submitting a comprehensive response to a Warning Letter from the FDA’s Office of Prescription Drug Promotion dated March 13, 2026. The letter concerned a podcast and a television advertisement related to ANKTIVA® promotional communications.
The company removed the cited podcast from its website and requested removal from third-party platforms, and stated the television advertisement was never broadcast. ImmunityBio describes immediate and planned corrective actions, including executive training, expanded Promotional Review Committee protocols, and use of external regulatory counsel, while reaffirming its commitment to accurate, balanced, and compliant advertising for ANKTIVA®.
ImmunityBio, Inc. reported that Nant Capital, LLC, an investment vehicle affiliated with Patrick Soon-Shiong, converted $25,000,000 of a Second Amended and Restated Convertible Promissory Note into 4,606,596 shares of common stock at $5.427 per share on March 31, 2026.
Following this derivative conversion, entities associated with Soon-Shiong indirectly held 251,018,873 shares of ImmunityBio common stock, and he also directly held 29,757,911 shares. The filing shows his influence through multiple affiliated entities with voting and dispositive power over these holdings.
ImmunityBio, Inc. amended its Revenue Interest Purchase Agreement, raising $75.0 million in additional non-dilutive financing in exchange for higher royalty-style payments on net sales in a defined global territory. The tiered revenue interest rate increased to 5.625%–12.50% of net sales, with future rate adjustments tied to whether cumulative payments reach $375.0 million by the end of 2029 and an overall cap at 195% of cumulative purchaser payments. Simultaneously, Nant Capital, an affiliate of the Executive Chairman, converted $25.0 million of a convertible promissory note into 4,606,596 common shares, reducing the note’s principal to $480.0 million. A related press release highlights that total committed capital under the royalty agreement has risen to $375 million and underscores recent global approvals for ANKTIVA®.
ImmunityBio director Barry J. Simon reported an open-market sale of common stock. On this Form 4, he sold 75,000 shares of ImmunityBio, Inc. common stock in an open-market transaction at a weighted average price of $12.0105 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024. After this sale, Simon directly holds 2,850,821 shares of ImmunityBio common stock, according to the filing.